Long-Bin Jeng

Dr. Long-Bin Jeng


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
WHWei-Yi Hsu
Wei-Yi Hsu
CCChao-Jung Chen
Chao-Jung Chen
YHYu-Chuen Huang
Yu-Chuen Huang
FTFuu-Jen Tsai
Fuu-Jen Tsai
LJLong-Bin Jeng
Long-Bin Jeng
CLChien-Chen Lai
Chien-Chen Lai
Urinary nucleosides are associated with many types of cancer. In this study, six targeted urinary nucleosides, namely adenosine, cytidine, 3-methylcytidine, 1-methyladenosine, inosine, and 2-deoxyguanosine, were chosen to evaluate their role as biomarkers of four different types of cancer: lung cancer, gastric cancer, colon cancer, and breast cancer. Urine samples were purified using solid-phase extraction (SPE) and then analyzed using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). The Mann-Whitney U test and Principal Component Analysis (PCA) were used to compare differences in urinary nucleosides between patients with one of four types of cancer and healthy controls. The diagnostic sensitivity of single nucleosides for different types of cancer ranged from 14% to 69%. In contrast, the diagnostic sensitivity of a set of six nucleosides ranged from 37% to 69%. The false-positive identification rate associated with the set of six nucleosides in urine was less than 2% compared with that of less than 5% for a single nucleoside. Furthermore, combining the set of six urinary nucleosides with carcinoembryonic antigen improved the diagnostic sensitivity for colon cancer. In summary, the study show that a set of six targeted nucleosides is a good diagnostic marker for breast and colon cancers but not for lung and gastric cancers.

25 March 2025 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
PYPo-Fu Yueh
Po-Fu Yueh
ICI-Tsang Chiang
I-Tsang Chiang
YWYueh-Shan Weng
Yueh-Shan Weng
YLYu-Chang Liu
Yu-Chang Liu
RWRaymond C. B. Wong
Raymond C. B. Wong
Fei-Ting HsuFei-Ting Hsu
Fei-Ting Hsu
Addressing the challenges of identifying suitable targets and effective delivery strategies is critical in pursuing therapeutic solutions for glioblastoma (GBM). This study focuses on the therapeutic potential of microRNA-124 (miR-124), known for its tumor-suppressing properties, by investigating its ability to target key oncogenic pathways in GBM. The results reveal that CDK4 and CDK6—cyclin-dependent kinases that promote cell cycle progression—are significantly overexpressed in GBM brain samples, underscoring their role in tumor proliferation and identifying them as critical targets for miR-124 intervention. However, delivering miRNA-based therapies remains a major obstacle due to the instability of RNA molecules and the difficulty in achieving targeted, efficient delivery. To address these issues, this research introduces an innovative, non-viral dual-gene delivery platform that utilizes umbilical cord mesenchymal stem cells (UMSCs) and their exosomes to transport miR-124 and programmed cell death protein-1 (PD-1). The efficacy of this dual-gene delivery system was validated using an orthotopic GBM model, which closely mimics the tumor microenvironment seen in patients. Experimental results demonstrate that the UMSC/miR-124-PD-1 complex and its exosomes successfully induce apoptosis in GBM cells, significantly inhibiting tumor growth. Notably, these treatments show minimal cytotoxic effects on normal glial cells, highlighting their safety and selectivity. Moreover, the study highlights the immunomodulatory properties of UMSC/miR-124-PD-1 and its exosomes, enhancing the activation of immune cells such as T cells and dendritic cells, while reducing immunosuppressive cells populations like regulatory T cells and myeloid-derived suppressor cells. The orchestrated dual-gene delivery system by UMSCs and exosomes showcased targeted tumor inhibition and positive immune modulation, emphasizing its potential as a promising therapeutic approach for GBM.

23 November 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
CCChih-Sheng Chiang
Chih-Sheng Chiang
BHBo-Jie Huang
Bo-Jie Huang
JCJui-Yu Chen
Jui-Yu Chen
WCWee Wei Chieng
Wee Wei Chieng
SLSeh Hong Lim
Seh Hong Lim
LJLong-Bin Jeng
Long-Bin Jeng
The anticancer properties of fucoidan have been widely studied in cancer research. However, the lack of safety information on the parenteral administration of fucoidan and its rapid clearance from the system have limited its application. Herein, we assessed the therapeutic efficacy and safety of fucoidan and developed fucoidan nanoparticles (FuNPs) to enhance their therapeutic effect in the mouse model of breast cancer. FuNPs were synthesized through the emulsion method, and the stable colloid has an average size of 216.3 nm. FuNPs were efficiently internalized into breast cancer cells in vitro, demonstrating an enhanced antitumor activity in comparison with free form fucoidan. After the treatment of FuNPs, the tumor progression was significantly inhibited in viv. The tumor volume was reduced by 2.49-fold compared with the control group. Moreover, the inhibition of the invasion of tumor cells into the lungs revealed the antimetastatic properties of the FuNPs. FuNPs, as naturally marine polysaccharide-based nanoparticles, have shown their broader therapeutic window and enhanced antimetastatic ability, opening an avenue to the development of the inherently therapeutic nanomedicines.

29 September 2010 in Clinica Chimica Acta
Verified
Journal Article
Closed access
EHEric C. Han
Eric C. Han
YLYing-Shiung Lee
Ying-Shiung Lee
WLWen-Sin Liao
Wen-Sin Liao
YLYu-Ching Liu
Yu-Ching Liu
HLHsin-Yi Liao
Hsin-Yi Liao
LJLong-Bin Jeng
Long-Bin Jeng

25 July 2024 in Advanced Science
Verified
Journal Article
Open access
SLSyuan‐Ling Lin
Syuan‐Ling Lin
YCYi‐Wen Chang
Yi‐Wen Chang
WLWei Lee
Wei Lee
CCChih‐Sheng Chiang
Chih‐Sheng Chiang
SLShih‐Ping Liu
Shih‐Ping Liu
WSWoei-Cherng Shyu
Woei-Cherng Shyu
The limited therapeutic strategies available for stroke leave many patients disabled for life. This study assessed the potential of programmed death‐ligand 1 (PD‐L1) and hepatocyte growth factor (HGF)‐engineered mesenchymal stem cell‐derived exosomes (EXO‐PD‐L1‐HGF) in enhancing neurological recovery post‐stroke. EXO‐PD‐L1‐HGF, which efficiently endocytosed into target cells, significantly diminishes the H 2 O 2 ‐induced neurotoxicity and increased the antiapoptotic proteins in vitro. EXO‐PD‐L1‐HGF attenuates inflammation by inhibiting T‐cell proliferation and increasing the number of CD8 + CD122 + IL‐10 + regulatory T cells. Intravenous injection of EXO‐PD‐L1‐HGF could target stromal cell‐derived factor‐1α (SDF‐1α + ) cells over the peri‐infarcted area of the ischemic brain through CXCR4 upregulation and accumulation in neuroglial cells post‐stroke. EXO‐PD‐L1‐HGF facilitates endogenous nestin + neural progenitor cell (NPC)‐induced neurogenesis via STAT3‐FOXO3 signaling cascade, which plays a pivotal role in cell survival and neuroprotection, thereby mitigating infarct size and enhancing neurological recovery in a murine stroke model. Moreover, increasing populations of the immune‐regulatory CD19 + IL‐10 + and CD8 + CD122 + IL‐10 + cells, together with reducing populations of proinflammatory cells, created an anti‐inflammatory microenvironment in the ischemic brain. Thus, innovative approaches employing EXO‐PD‐L1‐HGF intervention, which targets SDF‐1α + expression, modulates the immune system, and enhances the activation of resident nestin + NPCs, might significantly alter the brain microenvironment and create a niche conducive to inducing neuroplastic regeneration post‐stroke.

12 November 2018 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
TCTe-Hung Chen
Te-Hung Chen
HYHorng-Ren Yang
Horng-Ren Yang
LJLong-Bin Jeng
Long-Bin Jeng
SHShih-Chao Hsu
Shih-Chao Hsu
CHChia-Hao Hsu
Chia-Hao Hsu
WCWilliam Tzu-Liang Chen
William Tzu-Liang Chen